Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
Letter From The Editor

Ever since we were at the ADA meeting in Boston, there has been a lot of buzz about the artificial pancreas and how great it will be. We have even provided you with exclusive interviews with the lead researchers.

When we talk to prescribers and thought leaders, we often hear their skepticism about the safety of leaving the decision making up to a machine and that the FDA will never go along with approval. However other thought leaders will tell you that we trust computers and machines to keep us safe and that an artificial pancreas can probably do a better job at management than most of our patients.

Regardless of how you feel it is never good when a technology company has to let us know that they had some problems and that is why we are sorry that we have to report that Medtronic has issued a warning on their bolus wizard screen display and they recommend until a fix is found; that if your bolus calculation is more than 12 minutes old do not use to activate insulin delivery.



Announcements: Sunday, August 2, 7PM ET

From "dLife talked to "Biggest Loser" Erik Chopin and the experts, to find out more about weight loss challenges and success strategies for people with type 2. Plus, a senior that discovered weight lifting is a big benefit to his diabetes control. And dLife's Jim Turner speaks out on why marijuana and diabetes don't mix (parental discretion advised)." Sundays live online at at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at


We can make a difference!


Dave Joffe, Editor-in-chief

 … Read More

Scroll down for items in the current newsletter


There is an issue with the bolus screen display. The wrong bolus amount may appear on the screen due to an error with the Bolus Wizard. The company is telling patients that blood glucose levels based on a bolus that is more than 12 minutes old should not be used to activate insulin delivery.

Tool for your Practice

Diabetes Guide for Medical Professionals 

diabetes-guide-imageThis 22-page PDF for medical professionals from the Northwestern Memorial Foundation, Northwestern University, contains tips on how to use the videos and companion print materials, lesson plans for each module, and tips on how to work with patients in setting effective self-management goals. Download the guide (pdf) here. Educational patient videos can be found at


Product of the Week

altAuvi-Q (epinephrine injection, USP) is used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions. The first and only compact epinephrine auto‑injector for severe allergic reactions that talks you through the injection process step by step. It comes in two doses and automatically inserts the needle and the epinephrine dose, and then automatically retracts. Just put it on the outer thigh and push down it does all the work while verbally giving you instructions. More at the website at


Mobile App of the Week 



Blood Glucose Monitor is advanced and easy-to-use tool to watch for your blood glucose value on a daily basis and included tools for recording, editing, exporting data, calculating and drawing statistics and reports. More information.










Test Your Knowledge Question #792

At her last visit, your patient's labs showed a eGFR 55 ml/min/1.73 m2. At this visit, her labs measured an eGFR of 44 ml/min/1.73 m2. Dose reduction/cessation should be considered for all of the following agents EXCEPT:

A. Glyburide
B. Sitaglipitin
C. Metformin
D. Pioglitazone

For the complete question and answer, just follow this link. 

Diabetes In Control Has Over 16000 Studies & Articles In Our Archives

Quote of the Week!

"The moment in between what you once were, and who you are now becoming, is where the dance of life really takes place."
      ...Barbara de Angelis


Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week's newsletter: 

Diana Jules, University of South Florida College of Pharmacy
Michelle Lamour, Florida A&M College of Pharmacy
Bic Huynh, LECOM College of Pharmacy
Ashley Garringer, University of South Florida College of Pharmacy

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?

CME/CE of the Week
Mark Robbins, MD

Category: General Diabetes
Credits: .75